^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    VENTANA PD-L1 (SP142) Assay

    Company:
    Roche
    Related tests:
    1d
    VIM-Polyp: Multimodal Colon Polyp Dataset with Video, Histopathology, and Protein Expression. (PubMed, Sci Data)
    In combination with external datasets or pretrained models, the resource can help advance data-driven detection and characterisation work. The diverse range of polyps assigned to cancer stages from 201 patients makes this tool valuable for researchers and clinicians in furthering diagnosis and treatment.
    Journal • Video • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD34 (CD34 molecule) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    BRAF V600E • BRAF V600
    |
    VENTANA PD-L1 (SP142) Assay
    1d
    Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. (PubMed, J Clin Oncol)
    Combining atezolizumab with bevacizumab and chemotherapy did not significantly improve OS or PFS in patients with recurrent ovarian cancer ineligible for platinum. The safety profile was as expected from previous experience with these drugs.
    P3 data • Journal
    |
    PD-L1 expression
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel • pegylated liposomal doxorubicin
    5d
    Effect of Tissue Sample Type on The Evaluation of PD-L1 (SP142) Expression in Breast Cancer. (PubMed, Anticancer Res)
    For optimal PD-L1 assessment in breast cancer, surgical specimens from primary tumors without prior therapy are preferable due to larger evaluable tumor areas. For patients requiring neoadjuvant chemotherapy or with de novo Stage IV disease, multiple biopsies of primary tumors using thick needles before treatment, with attention being paid to sampling tumor margins to account for potential immune-excluded phenotypes, are recommended.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    VENTANA PD-L1 (SP142) Assay
    6d
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=792, Recruiting, Hoffmann-La Roche | N=580 --> 792 | Trial completion date: May 2028 --> Sep 2030 | Trial primary completion date: May 2028 --> Sep 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PD-L1 expression • PIK3CA mutation
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    8d
    The changes of CD47 and PD-L1 (SP142) before and after neoadjuvant therapy help predict prognosis of patients with stage IIIA-N2 non-small cell lung cancer. (PubMed, Int J Clin Oncol)
    Post-NAT CD47 and PD-L1 (SP142) levels were reduced in IIIA-N2 NSCLC patients. ΔCD47 and ΔPD-L1 (SP142) levels linked to clinicopathological characteristics and predicted prognosis.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    VENTANA PD-L1 (SP142) Assay
    10d
    Sarcomatoid carcinoma of the prostate - A single institution experience with emphasis on molecular genetic findings. (PubMed, Hum Pathol)
    This study sheds light on the molecular landscape of SCP, which may be valuable to elucidate the prognostic and therapeutic implications for this uncommon disease.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
    2ms
    PD-L1 expression in cerebrospinal fluid for leptomeningeal metastasis from solid tumors: preliminary assessment of clinical implications. (PubMed, Front Immunol)
    Our study establishes a robust methodology for detecting CSF PD-L1 expression using ThinPrep LBC with immunocytochemistry for LM patients. This approach suggests potential utility of CSF PD-L1 expression as a biomarker for guiding intrathecal immunotherapy for LM from solid tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
    2ms
    NADiR: Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Feb 2027
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 amplification • HER-2 negative • PD-L1 negative
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    2ms
    PD-L1 expression pattern as predictive factor of biological behaviour in intracranial meningiomas: A single-center retrospective study. (PubMed, Eur J Clin Invest)
    Granular cytoplasmic and membranous PD-L1 expression patterns are significantly associated with tumour grade, recurrence and progression, suggesting their potential role as prognostic biomarkers in meningiomas.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    VENTANA PD-L1 (SP142) Assay
    3ms
    A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=60, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2028 --> Aug 2027
    Trial completion date • IO biomarker
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab)
    3ms
    PD-L1 expression in locally advanced cervical cancer: A pilot cross clone comparison study. (PubMed, Int J Radiat Oncol Biol Phys)
    Our findings highlight the differences in PD-L1 expression when different antibody clones are used for PD-L1 IHC. Though overall positivity rate was not different, there was heterogeneity at per patient level. Further investigation is needed into PD-L1 expression.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay
    3ms
    Association of Programmed Death-Ligand 1 Expression in Relation to Tumor-Infiltrating Lymphocyte Concentration and Histological Type with Outcomes of Triple-Negative Breast Cancer. (PubMed, J Nippon Med Sch)
    The rate of PD-L1 positivity was higher in TIL-H patients. Patients classified as TIL-H and PD-L1-positive had worse TNBC outcomes.
    Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    VENTANA PD-L1 (SP142) Assay